Increased expression of HAPLN3 has been reported in breast cancer [112] while TSG-6 has been found to be increased in colon cancer, ovarian cancer, bladder cancer, and prostate cancer [87,88,89] In colon and ovarian cancer, higher TSG-6 levels were correlated with poor prognosis [89]. Here, TNFAIP6 is linked to prostate cancer.